Skip to content
NeuroTechGuide

Empatica wins FDA clearance for continuous Parkinson's symptom monitoring with wearables

The platform tracks tremor, slowness of movement, dyskinesia, sleep and medication use to support clinical care.

In briefRegulationConsumer

Empatica has received FDA 510(k) clearance, its twelfth, for a Parkinson’s disease monitoring platform. It combines clinical-grade wearables, a patient app and a clinician portal to continuously track bradykinesia, dyskinesia, tremor, sleep and medication adherence. The platform builds on Empatica’s 2025 acquisition of PKG Health. The company cites research showing that adding wearable data improved prediction of the right medication regimen to 86.9% accuracy.

Continuous at-home data could help doctors fine-tune treatments, including deep brain stimulation, between clinic visits.

Learn more: Neural data · Empatica

Share:XLinkedInBlueskyEmail

More news